Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.61 |
| ▸ | CNR2 | P34972 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497875 | 1.00 | CNR1 (0.61) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL2818345 | 0.96 | CNR1 (0.60) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL9342889 | 0.91 | CNR2 (0.58) | CNR1CNR2TSHRKDM4EHSD17B10 | |
| SCHEMBL3017718 | 0.90 | TSHR (0.53) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL15897843 | 0.88 | PKM (0.52) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL6948881 | 0.87 | CNR2 (0.61) | CNR1CNR2TSHRKDM4EHSD17B10 | |
| SCHEMBL8874913 | 0.87 | CNR1 (0.66) | CNR1CNR2TSHRKDM4EHSD17B10 | |
| SCHEMBL24221989 | 0.86 | CNR1 (0.65) | CNR1CNR2CDC25A | |
| SCHEMBL28985446 | 0.86 | TSHR (0.50) | CNR1CNR2TSHRCYP1A2CYP3A4 | |
| SCHEMBL15897842 | 0.85 | PKM (0.55) | CNR1CNR2TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022006498-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC. (CA) | 2022-01-06 | — | — | WO | disclosed |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2021-02-11 | — | — | US | disclosed |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | RANDOX LABORATORIES LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | RANDOX LABORATORIES LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-2950103-B1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE 3-ADAMANTANYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | RANDOX LABORATORIES LTD (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | NORTHERN BANK LIMITED (IE) | 2015-12-03 | — | — | US | disclosed |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | NORTHERN BANK LIMITED (IE) | 2015-12-03 | — | — | US | disclosed |
| EP-2950103-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE 3-ADAMANTANYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | Randox Laboratories Ltd. (GB) | 2015-12-02 | — | — | EP | disclosed |
| EP-2950103-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE 3-ADAMANTANYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | Randox Laboratories Ltd. (GB) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014167530-A1 | CANNABINOID COMPOUNDS | BOWDEN MATTHEW JAMES (NZ) | 2014-10-16 | — | — | WO | disclosed |
| EP-0829474-B1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN SEIFUN GROUP INC (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6096746-A | Indazole compound containing a monocyclic amine structure | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5945434-A | TREATMENT OF GASTROINTESTINAL DISORDERS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0708105-B1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0829474-A1 | INDAZOLE DERIVATIVES HAVING MONOCYCLIC AMINO GROUP | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5684003-A | GASTROINTESTINAL DISORDERS OR ANTIULCER AGENTS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-11-04 | — | — | US | disclosed |
| EP-0708105-A1 | 5-HT4 receptor agonists | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR1 1/4885CNR2 2/4885TSHR 3605/4885 |
| US-20150346227-A1 | IMMUNOASSAY FOR SYNTHETIC CANNABINOIDS OF THE ADAMANTYL INDAZOLE/INDOLE-3-CARBOXAMIDE FAMILY | CNR2, CNR1, IDO1 | CNR1 2/4885CNR2 1/4885TSHR 1266/4885 |
| US-20210038559-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | CNR1, CNR2, CD74 | CNR1 1/4885CNR2 2/4885TSHR 3699/4885 |
| US-10591497-B2 | Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family | CNR2, CNR1, IDO1 | CNR1 2/4885CNR2 1/4885TSHR 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.